Phase I Study of BMS-986299, an NLRP3 Agonist, As Monotherapy and in Combination with Nivolumab and Ipilimumab in Patients with Advanced Solid Tumors

Blessie E. Nelson,Shaun O'Brien, Rahul A. Sheth,David S. Hong,Aung Naing, Xiaoping Zhang,Amy Xu,Lora Hamuro, Rasika Suryawanshi, Derrick Mckinley, Ruslan D. Novosiadly, Sarina A. Piha-Paul

JOURNAL FOR IMMUNOTHERAPY OF CANCER（2025）

Cited 0|Views0

Key words

Intratumoral,Combination therapy,Immune Checkpoint Inhibitor,Solid tumor,Tumor microenvironment - TME

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined